Therapeutic Response

BRCA2 pathogenic variants status confers therapeutic sensitivity to Abiraterone acetate in combination with Olaparib and Prednisolone in patients with Prostate Adenocarcinoma.

Statements

Source and description

Lynparza (olaparib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.